Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients

AIDS

Volumn 15, Issue 1, 2001, Pages 71-75

  Marzolini, Catia ^a   Telenti, Amalio ^a   Decosterd, Laurent A ^a   Greub, Gilbert ^a   Biollaz, Jérôme ^a   Buclin, Thierry ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

CNS side effects; Drug monitoring; Efavirenz; Plasma levels; Treatment failure

Indexed keywords

EFAVIRENZ;

ADULT; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG TOLERABILITY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PRIORITY JOURNAL; TREATMENT FAILURE;

ADULT; AGED; ANTI-HIV AGENTS; CENTRAL NERVOUS SYSTEM; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; OXAZINES; PREDICTIVE VALUE OF TESTS; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT FAILURE; VIRAL LOAD;

EID: 0035808574     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200101050-00011     Document Type: Article

References (20)

1. Efavirenz
2. Non nucleoside reverse transcriptase inhibitors
3. Review of NNRTIs: Today and tomorrow
4. Pharmacologic considerations for therapeutic success with antiretroviral agents
5. What are the perceived advantages and disadvantages of non-nucleoside reverse transcriptase inhibitors as firstline therapy?
6. Durability of antiviral activity of efavirenz in combination with indinavir (IDV)
7. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults
8. Efavirenz is well tolerated and highly efficacious in combination with the nucleoside stavudine (d4T) + didanosine (ddl) or d4T + lamivudine (3TC)
9. Population pharmacokinetics of efavirenz in phase II studies and relationship with efficacy
10. Efavirenz in the management of HIV infection
11. Efavirenz: Practicalities, considerations and new issues
12. Tolerability and efficacy of SUSTIVA in the European Expanded Access Programme
13. Pharmacologic considerations for therapeutic success with antiretroviral agents
14. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: Pharmacological data from the Viradapt Study
15. Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir, nelfinavir and the non-nucleoside reverse transcriptase inhibitor efavirenz by HPLC after solid-phase extraction
16. Pharmacokinetics of efavirenz (efavirenz) alone and in combination therapy with nelfinavir (NFV) in HIV-1 infected patients
17. Pharmacokinetics of the triple combination of saquinavir, ritonavir and efavirenz in HIV positive patients
18. Dose-escalating prescription of efavirenz (EFV) reduces the incidence of central nervous system (CNS) severe adverse events